Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P et al. N Engl J Med. 2016 Apr 28;374(17):1621-1634.

Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractorymultiple myeloma: dose selection for a phase 3 maintenance study.
Gupta N et al. Invest New Drugs. 2016 Apr 2. [Epub ahead of print].

Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies including Multiple Myeloma: Study NPI-0052-102 Final Results.
Harrison SJ et al. Clin Cancer Res. 2016 Apr 26. pii: clincanres.2616.2015. [Epub ahead of print].

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Moreau P et al. Drugs. 2016 Apr 25. [Epub ahead of print].

Importins and exportins as therapeutic targets in cancer.
Mahipal A et al. Pharmacol Ther. 2016 Apr 22. pii: S0163-7258(16)30048-1. doi: 10.1016/j.pharmthera.2016.03.020. [Epub ahead of print].

T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.
Hossain NM et al. Curr Hematol Malig Rep. 2016 Apr 19. [Epub ahead of print].

Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus Bd for relapsed/refractory multiple myeloma.
Jakubowiak A et al. Blood. 2016 Apr 18. pii: blood-2016-01-694604. [Epub ahead of print].

Programming the immune checkpoint to treat hematologic malignancies.
Vick E et al. Expert Opin Investig Drugs. 2016 Apr 25:1-16. [Epub ahead of print].

Development of chimeric antigen receptors for multiple myeloma.
Martínez-Cingolani C et al. Biochem Soc Trans. 2016 Apr 15;44(2):397-405. doi: 10.1042/BST20150280.

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Amorim S et al. Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A et al. Lancet Oncol. 2016 Mar 31. pii: S1470-2045(15)00584-7. doi: 10.1016/S1470-2045(15)00584-7. [Epub ahead of print].

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR et al. Eur J Cancer. 2016 Mar 31;60:12-25. doi: 10.1016/j.ejca.2016.02.010. [Epub ahead of print].

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn TJ et al. Br J Haematol. 2016 Apr;173(2):253-9. doi: 10.1111/bjh.13946. Epub 2016 Apr 4.

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
McCudden C et al. Clin Chem Lab Med. 2016 Mar 30. pii: /j/cclm.ahead-of-print/cclm-2015-1031/cclm-2015-1031.xml. doi: 10.1515/cclm-2015-1031. [Epub ahead of print].

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
Lendvai N et al. Blood. 2016 Mar 28. pii: blood-2016-01-694786. [Epub ahead of print].

Sorafenib for the treatment of multiple myeloma.
Gentile M et al. Expert Opin Investig Drugs. 2016 Apr 6:1-7. [Epub ahead of print].